# Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

> **NCT01944943** · PHASE2 · TERMINATED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 31 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Indolent Non-hodgkin Lymphoma
- Primary Central Nervous System Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01944943
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-10
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2017-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01944943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01944943, "Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01944943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*